While some studies have reported its upregulation in breast and colorectal cancers, suggesting a potential oncogenic function, others have reported its downregulation in glioma, where it acts as a tumor suppressor by targeting oncogenes such as CORO2A, APC2, WNT7A, and BOC [27]. This evidence concerns the gene CORO2A and neoplasm.